Last edition
News about "Kenneth Culver"
Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC
Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.
Kenneth Culver | 30/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members